About OncoImmunity
OncoImmunity is a company based in Oslo (Norway) founded in 2014 was acquired by NEC in July 2019.. OncoImmunity has raised $7.37 million across 6 funding rounds from investors including NEC, European Union and EIC Fund. The company has 16 employees as of December 31, 2022. OncoImmunity offers products and services including NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations. OncoImmunity operates in a competitive market with competitors including Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.
- Headquarter Oslo, Norway
- Employees 16 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nec Oncoimmunity As
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OncoImmunity
OncoImmunity offers a comprehensive portfolio of products and services, including NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI tool for immune profiling in cancer vaccine research
Predicts epitopes for infectious disease vaccines
Simulates biological processes for therapy development
Unlock access to complete
Unlock access to complete
Funding Insights of OncoImmunity
OncoImmunity has successfully raised a total of $7.37M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $57.8 thousand completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $57,804
-
First Round
First Round
(01 Jun 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2021 | Amount | Grant - OncoImmunity | Valuation |
investors |
|
| May, 2019 | Amount | Grant - OncoImmunity | Valuation |
investors |
|
| Dec, 2018 | Amount | Grant - OncoImmunity | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OncoImmunity
OncoImmunity has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include NEC, European Union and EIC Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Cloud-based IT and networking solutions are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OncoImmunity
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OncoImmunity
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oncoimmunity Comparisons
Competitors of OncoImmunity
OncoImmunity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for various diseases
|
|
| domain | founded_year | HQ Location |
An agentic AI platform is developed for biomedical research insights.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| domain | founded_year | HQ Location |
AI platform used for extracting antibody data from scientific papers.
|
|
| domain | founded_year | HQ Location |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| domain | founded_year | HQ Location |
AI-driven drug discovery platform for the treatment of cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oncoimmunity
Frequently Asked Questions about OncoImmunity
When was OncoImmunity founded?
OncoImmunity was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Where is OncoImmunity located?
OncoImmunity is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Is OncoImmunity a funded company?
OncoImmunity is a funded company, having raised a total of $7.37M across 6 funding rounds to date. The company's 1st funding round was a Grant of $2.49M, raised on Jun 01, 2017.
How many employees does OncoImmunity have?
As of Dec 31, 2022, the latest employee count at OncoImmunity is 16.
What is the annual revenue of OncoImmunity?
Annual revenue of OncoImmunity is $1.34M as on Mar 31, 2022.
What does OncoImmunity do?
OncoImmunity was established in 2014 in Oslo, Norway, as a bioinformatics firm. Machine-learning tools are utilized to predict immunogenic neoantigens, addressing gaps in personalized cancer immunotherapy. Patient selection for treatments is facilitated, and targets for vaccines and cell therapies are identified within actionable timelines. Operations focus on clinical applications in oncology, with incubation support from the Oslo Cancer Cluster.
Who are the top competitors of OncoImmunity?
OncoImmunity's top competitors include Owkin, Formation Bio and XtalPi.
What products or services does OncoImmunity offer?
OncoImmunity offers NEC Immune Profiler, NEC B-cell Epitope Predictor, and Digital Twin Simulations.
Who are OncoImmunity's investors?
OncoImmunity has 3 investors. Key investors include NEC, European Union, and EIC Fund.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.